Inovio Pharmaceuticals, Inc. today unveiled that the company has developed a new DNA-based cytokine immune activator, interleukin -33 , that in combination with optimized DNA vaccines delivered by electroporation increased the potency and efficacy of the therapeutic response to the DNA vaccines in a preclinical study.
http://ift.tt/1g3JLwL
http://ift.tt/1g3JLwL
No comments:
Post a Comment